Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report [Internet].

Gartlehner G, Hansen RA, Reichenpfader U, Kaminski A, Kien C, Strobelberger M, Van Noord M, Thieda P, Thaler K, Gaynes B.

Portland (OR): Oregon Health & Science University; 2011 Mar.

2.

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S.

Portland (OR): Oregon Health & Science University; 2010 Jul.

3.

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN.

Ann Intern Med. 2008 Nov 18;149(10):734-50. Review.

PMID:
19017592
4.

Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review [Internet].

Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, Mager U, Gaynes BN, Thieda P, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Dec.

5.

Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet].

Smith B, Peterson K, Fu R, McDonagh M, Thakurta S.

Portland (OR): Oregon Health & Science University; 2011 Apr.

6.

Second-generation antidepressants for preventing seasonal affective disorder in adults.

Gartlehner G, Nussbaumer B, Gaynes BN, Forneris CA, Morgan LC, Kaminski-Hartenthaler A, Greenblatt A, Wipplinger J, Lux LJ, Sonis JH, Hofmann J, Van Noord MG, Winkler D.

Cochrane Database Syst Rev. 2015 Nov 8;(11):CD011268. doi: 10.1002/14651858.CD011268.pub2. Review.

PMID:
26558418
7.

Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.

Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN.

Ann Intern Med. 2011 Dec 6;155(11):772-85. doi: 10.7326/0003-4819-155-11-201112060-00009. Review.

PMID:
22147715
8.

Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.

Olthuis JV, Watt MC, Bailey K, Hayden JA, Stewart SH.

Cochrane Database Syst Rev. 2016 Mar 12;3:CD011565. doi: 10.1002/14651858.CD011565.pub2. Review.

PMID:
26968204
9.

Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.

Olthuis JV, Watt MC, Bailey K, Hayden JA, Stewart SH.

Cochrane Database Syst Rev. 2015 Mar 5;(3):CD011565. doi: 10.1002/14651858.CD011565. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD011565.

PMID:
25742186
10.

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS.

Ann Intern Med. 2005 Sep 20;143(6):415-26. Review.

PMID:
16172440
11.

Drug Class Review: Neuropathic Pain: Final Update 1 Report [Internet].

Selph S, Carson S, Fu R, Thakurta S, Low A, McDonagh M.

Portland (OR): Oregon Health & Science University; 2011 Jun.

12.

Second-generation antidepressants for seasonal affective disorder.

Thaler K, Delivuk M, Chapman A, Gaynes BN, Kaminski A, Gartlehner G.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008591. doi: 10.1002/14651858.CD008591.pub2. Review.

PMID:
22161433
13.

Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.

Nussbaumer B, Morgan LC, Reichenpfader U, Greenblatt A, Hansen RA, Van Noord M, Lux L, Gaynes BN, Gartlehner G.

CNS Drugs. 2014 Aug;28(8):699-712. doi: 10.1007/s40263-014-0169-z. Review.

PMID:
24794101
14.

Off-Label Use of Atypical Antipsychotics: An Update [Internet].

Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep.

15.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
16.

Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review.

Thaler KJ, Morgan LC, Van Noord M, Gaynes BN, Hansen RA, Lux LJ, Krebs EE, Lohr KN, Gartlehner G.

Depress Anxiety. 2012 Jun;29(6):495-505. doi: 10.1002/da.21951. Review.

PMID:
22553134
17.

Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet].

Peterson K, McDonagh M, Thakurta S, Dana T, Roberts C, Chou R, Helfand M.

Portland (OR): Oregon Health & Science University; 2010 Nov.

19.

Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, Lohr KN.

Drug Saf. 2008;31(10):851-65. Review.

PMID:
18759509
20.

Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].

Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A.

Portland (OR): Oregon Health & Science University; 2010 Aug.

Items per page

Supplemental Content

Support Center